Login to Your Account

Psyadon Initiates Phase III in Lesch-Nyhan Disorder

By Marie Powers
Staff Writer

Wednesday, February 27, 2013
Small biotech Psyadon Pharmaceuticals made a big clinical move by initiating a Phase III study of ecopipam – its only asset – for the treatment of self-injurious behaviors in the ultra-rare orphan disease Lesch-Nyhan disorder.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription